Simrat  Randhawa net worth and biography

Simrat Randhawa Biography and Net Worth

Dr. Randhawa brings over 20 years of clinical practice and pharmaceutical industry experience to Dianthus. He most recently served as Senior Vice President of Clinical and Medical Affairs at Aurinia Pharmaceuticals, an autoimmune-focused company, where he supported the clinical development of voclosporin and investor relations. Dr. Randhawa has held a number of senior commercial and medical leadership roles in the autoimmune and rare disease spaces within large pharma and biotech companies such as Novartis and Biomarin. Previously, he supported business development opportunities and integration needs in the health care sector while at McKinsey Consulting. Dr. Randhawa completed his M.D. at Drexel University and received his M.B.A. from Columbia University.

What is Simrat Randhawa's net worth?

The estimated net worth of Simrat Randhawa is at least $37,640.00 as of September 21st, 2023. Randhawa owns 2,000 shares of Dianthus Therapeutics stock worth more than $37,640 as of May 14th. This net worth estimate does not reflect any other assets that Randhawa may own. Additionally, Randhawa receives an annual salary of $338,160.00 as Insider at Dianthus Therapeutics. Learn More about Simrat Randhawa's net worth.

How old is Simrat Randhawa?

Randhawa is currently 54 years old. There are 4 older executives and no younger executives at Dianthus Therapeutics. The oldest executive at Dianthus Therapeutics is Mr. Marino Garcia M.B.A., President, CEO, Secretary & Director, who is 58 years old. Learn More on Simrat Randhawa's age.

What is Simrat Randhawa's salary?

As the Insider of Dianthus Therapeutics, Inc., Randhawa earns $338,160.00 per year. The highest earning executive at Dianthus Therapeutics is Mr. Marino Garcia M.B.A., President, CEO, Secretary & Director, who commands a salary of $496,020.00 per year. Learn More on Simrat Randhawa's salary.

How do I contact Simrat Randhawa?

The corporate mailing address for Randhawa and other Dianthus Therapeutics executives is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . Dianthus Therapeutics can also be reached via phone at 857-242-0170 and via email at investor@magentatx.com. Learn More on Simrat Randhawa's contact information.

Has Simrat Randhawa been buying or selling shares of Dianthus Therapeutics?

Simrat Randhawa has not been actively trading shares of Dianthus Therapeutics during the past quarter. Most recently, on Thursday, September 21st, Simrat Randhawa bought 2,000 shares of Dianthus Therapeutics stock. The stock was acquired at an average cost of $13.20 per share, with a total value of $26,400.00. Following the completion of the transaction, the insider now directly owns 2,000 shares of the company's stock, valued at $26,400. Learn More on Simrat Randhawa's trading history.

Simrat Randhawa Insider Trading History at Dianthus Therapeutics

See Full Table

Simrat Randhawa Buying and Selling Activity at Dianthus Therapeutics

This chart shows Simrat Randhawa's buying and selling at Dianthus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Dianthus Therapeutics Company Overview

Dianthus Therapeutics logo
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Read More

Today's Range

Now: $18.82
Low: $18.62
High: $19.58

50 Day Range

MA: $19.68
Low: $14.86
High: $24.34

2 Week Range

Now: $18.82
Low: $13.37
High: $32.27

Volume

52,180 shs

Average Volume

267,262 shs

Market Capitalization

$604.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48